Cambridge Cognition Holdings (FRA:1M7) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1M7 Cambridge Cognition Holdings PLC FRA:1M7
52 GF Score
Price €0.35
GF Value €0.35
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Cambridge Cognition Holdings FFO per Share?

FFO per Share only applies to REITs.

FRA:1M7
52GF Score
Cambridge Cognition Holdings PLC FRA:1M7
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cambridge Cognition Holdings (FRA:1M7) Overvalued in 2026?

Based on GuruFocus' analysis, Cambridge Cognition Holdings stock appears to be undervalued. The current stock price of €0.35 is trading 0.6% below its estimated GF Value™ of €0.35. GuruFocus considers Cambridge Cognition Holdings to be Fairly Valued.

Key valuation signals for FRA:1M7:

  • FFO per Share:
  • GF Value™: €0.35 vs. price of €0.35 (0.6% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the FRA:1M7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cambridge Cognition Holdings Business Description

Other Exchanges COG:UK
Address Tunbridge Lane, Tunbridge Court, Bottisham, Cambridge, GBR, CB25 9TU
Cambridge Cognition Holdings PLC is a neuroscience digital health company specializing in the measurement of clinical outcomes in neurological disorders. It develops and commercialises neuroscience technologies to assess cognitive function for sale across the world. The company's products include CANTAB web-based assessments, Electronic questionnaires and scales (eCOA), NeuroVocalix Winterlight, a voice analysis tool to assess cognitive changes, high-frequency testing kits, and Clinpal, among others. Its operating segments are: Clinical studies, which generate maximum revenue, Academic research, Professional Healthcare, and Consumer Health & Wellness. Geographically, the company generates maximum revenue from the USA, and the rest from the UK, the European Union, and the Rest of the world.
52GF Score

Get the complete analysis for FRA:1M7

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.35
Price
€0.35
GF Value